Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer—Reply

Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in... Letters although mild irAEs, such as vitiligo and endocrine irAEs, were our article (Table 3). We apologize for this typographical strongly associated with RFS, there was no significant asso- error. As pointed out in the comments by Suijkerbuijk et al ciation with severe (grade 3 or greater) irAEs. and in the Results section of our article, the occurrence of a We very recently reported that accelerated immunosup- severe irAE among patients treated with pembrolizumab pression with anti–tumor necrosis factor (TNF) for severe irAEs was not significantly associated with a prolonged recurrence- compromises survival in patients with advanced melanoma. free survival. However, longer follow-up would be necessary Analyzing data from the Dutch Melanoma Treatment Registry, to better assess the outcome of this limited group of 36 we showed that patients with severe irAEs who were treated patients who developed a grade 3 or 4 irAE after the start of with steroids had a significantly better survival than patients pembrolizumab. without severe irAEs. This survival advantage disappeared The study by Verheijden et al reported that the positive when anti-TNF was used for steroid-refractory irAEs. As sec- influence of the occurrence of irAEs on overall survival was ond-line immunosuppressants are typically indicated http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer—Reply

Loading next page...
 
/lp/american-medical-association/risk-benefit-comparisons-between-shorter-and-longer-durations-of-vvt6Va4Ejv
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.2262
Publisher site
See Article on Publisher Site

Abstract

Letters although mild irAEs, such as vitiligo and endocrine irAEs, were our article (Table 3). We apologize for this typographical strongly associated with RFS, there was no significant asso- error. As pointed out in the comments by Suijkerbuijk et al ciation with severe (grade 3 or greater) irAEs. and in the Results section of our article, the occurrence of a We very recently reported that accelerated immunosup- severe irAE among patients treated with pembrolizumab pression with anti–tumor necrosis factor (TNF) for severe irAEs was not significantly associated with a prolonged recurrence- compromises survival in patients with advanced melanoma. free survival. However, longer follow-up would be necessary Analyzing data from the Dutch Melanoma Treatment Registry, to better assess the outcome of this limited group of 36 we showed that patients with severe irAEs who were treated patients who developed a grade 3 or 4 irAE after the start of with steroids had a significantly better survival than patients pembrolizumab. without severe irAEs. This survival advantage disappeared The study by Verheijden et al reported that the positive when anti-TNF was used for steroid-refractory irAEs. As sec- influence of the occurrence of irAEs on overall survival was ond-line immunosuppressants are typically indicated

Journal

JAMA OncologyAmerican Medical Association

Published: Aug 25, 2020

References